Patents by Inventor Akira Togashi
Akira Togashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11974444Abstract: There is provided a solid-state image sensor, a solid-state imaging device, an electronic apparatus, and a method of manufacturing a solid-state image sensor capable of improving characteristics. There is provided a solid-state image sensor including a stacked structure that includes a semiconductor substrate, a first photoelectric converter provided above the semiconductor substrate and converting light into charges, and a second photoelectric converter provided above the first photoelectric converter and converting light into charges, where the first photoelectric converter and the second photoelectric converter include a photoelectric conversion stacked structure in which a common electrode, a photoelectric conversion film, and a readout electrode are stacked so that the first photoelectric converter and the second photoelectric converter are in a line-symmetrical relationship with each other with a vertical plane perpendicular to a stacking direction of the stacked structure as an axis of symmetry.Type: GrantFiled: June 11, 2019Date of Patent: April 30, 2024Assignees: SONY CORPORATION, SONY SEMICONDUCTOR SOLUTIONS CORPORATIONInventors: Hideaki Togashi, Iwao Yagi, Masahiro Joei, Fumihiko Koga, Kenichi Murata, Shintarou Hirata, Yosuke Saito, Akira Furukawa
-
Publication number: 20240096914Abstract: Provided is an imaging element including a photoelectric conversion unit formed by stacking a first electrode, a photoelectric conversion layer and a second electrode. The photoelectric conversion unit further includes a charge storage electrode which is disposed to be spaced apart from the first electrode and disposed opposite to the photoelectric conversion layer via an insulating layer. The photoelectric conversion unit is formed of N number of photoelectric conversion unit segments, and the same applies to the photoelectric conversion layer, the insulating layer and the charge storage electrode. An nth photoelectric conversion unit segment is formed of an nth charge storage electrode segment, an nth insulating layer segment and an nth photoelectric conversion layer segment. As n increases, the nth photoelectric conversion unit segment is located farther from the first electrode. A thickness of the insulating layer segment gradually changes from a first to Nth photoelectric conversion unit segment.Type: ApplicationFiled: November 29, 2023Publication date: March 21, 2024Applicant: SONY GROUP CORPORATIONInventors: Akira FURUKAWA, Yoshihiro ANDO, Hideaki TOGASHI, Fumihiko KOGA
-
Patent number: 8975086Abstract: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides composed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.Type: GrantFiled: August 21, 2009Date of Patent: March 10, 2015Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Akira Togashi
-
Patent number: 8512944Abstract: Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.Type: GrantFiled: August 25, 2009Date of Patent: August 20, 2013Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Ryuji Hamamoto, Akira Togashi
-
Patent number: 8435749Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.Type: GrantFiled: June 30, 2009Date of Patent: May 7, 2013Assignee: Oncotherapy Science, Inc.Inventors: Akira Togashi, Masakazu Katsu, Megumi Takayanagi, Hiroki Yoshioka, Pohsing Ng, Yasuhiro Shiba, Yusuke Nakamura, Keigo Endo
-
Publication number: 20120128584Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.Type: ApplicationFiled: June 30, 2009Publication date: May 24, 2012Applicant: Oncotherapy Science, Inc.Inventors: Akira Togashi, Masakazu Katsu, Megumi Takayanagi, Hiroki Yoshioka, Pohsing Ng, Yasuhiro Shiba, Yusuke Nakamura, Keigo Endo
-
Publication number: 20120022131Abstract: The present invention provides methods for detecting and diagnosing cancer, such methods involving the determination of the expression level of the RQCD1, GIGYF1 or GIGYF2 genes. These genes were discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer and methods for treating cancer. Moreover, the present invention provides siRNAs targeting the RQCD1, GIGYF1 and/or GIGYF2 genes, all of which are suggested to be useful in the treatment of cancer.Type: ApplicationFiled: August 13, 2009Publication date: January 26, 2012Applicant: Oncotherapy Science Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Akira Togashi
-
Publication number: 20120010266Abstract: The present invention relates to the roles played by the TBC1D7 genes in cancer, in particular, lung cancer or esophageal cancer, or carcinogenesis and features a method for treating and/or preventing cancer, in particular, lung cancer or esophageal cancer by administering a double-stranded molecule against one or more of the TBC1D7 genes or a composition, vector or cell containing such a double stranded molecule. The present invention also features methods for diagnosing lung or assessing/determining the prognosis of a patient with lung, especially NSCLC or SCLC, or esophageal cancer, using one or more over-expressed genes selected from among TBC1D7. To that end, TBC1D7 may serve as a novel biomarker for lung cancer or esophageal cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung or esophageal cancer, using as an index for their effect on the over-expression of one or more of TBC1D7 in the lung cancer or esophageal cancer.Type: ApplicationFiled: August 14, 2009Publication date: January 12, 2012Applicant: Oncotherapy Science Inc.,Inventors: Yusuke Nakamura, Yataro Daigo, Akira Togashi
-
Publication number: 20110319280Abstract: The invention features methods for detecting lung cancer or esophageal cancer, by detecting over-expression of ECT2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing lung cancer or esophageal cancer, based on the over-expression of ECT2 in the lung cancer or esophageal cancer, the cell proliferation function of ECT2. Also, provided are a method for treating lung cancer or esophageal cancer by administering a double-stranded molecule against the ECT2 gene or an antibody against ECT2 protein. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.Type: ApplicationFiled: July 16, 2009Publication date: December 29, 2011Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Akira Togashi
-
Publication number: 20110262463Abstract: The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.Type: ApplicationFiled: August 24, 2009Publication date: October 27, 2011Applicant: Oncotherapy Science ,Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Akira Togashi
-
Publication number: 20110263679Abstract: Objective methods for diagnosing a predisposition to developing pancreatic cancer and prostate cancer, particularly pancreatic ductal adenocarcinoma (PDAC) and castration-resistant prostate cancer, are described herein. In one embodiment, the diagnostic method involves the step of determining an expression level of C12ORF48 using siRNAs targeting the C12ORF48 gene. The invention also features products such as siRNAs as well as to compositions containing them. The present invention further provides methods of screening for therapeutic agents useful in the treatment of C12ORF48 associated disease, such as a cancer, e.g. pancreatic cancer and prostate cancer, as well as methods of inhibiting the cell growth and treating or alleviating one or more disease symptoms. The invention also features products such as double stranded molecules, as well as vectors and compositions containing them.Type: ApplicationFiled: August 21, 2009Publication date: October 27, 2011Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Akira Togashi
-
Publication number: 20110251090Abstract: The present invention relates to the roles played by TTLL4 genes in pancreatic cancer carcinogenesis and features a method for treating or preventing pancreatic cancer by administering a double-stranded molecule against one or more of the TTLL4 genes or a composition, vector or cell containing such a double stranded molecule. Also, disclosed are methods of identifying compounds for treating and preventing pancreatic cancer, using as an index their effect on the over-expression of TTLL4 in the pancreatic cancer cell.Type: ApplicationFiled: August 21, 2009Publication date: October 13, 2011Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Akira Togashi
-
Publication number: 20110237518Abstract: The present invention provides therapeutic agents and methods for treating cancer using the polypeptides posed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer.Type: ApplicationFiled: August 21, 2009Publication date: September 29, 2011Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Toyomasa Katagiri, Akira Togashi
-
Publication number: 20110160293Abstract: Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.Type: ApplicationFiled: August 25, 2009Publication date: June 30, 2011Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke Nakamura, Ryuji Hamamoto, Akira Togashi
-
Publication number: 20110160288Abstract: The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody. The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5.Type: ApplicationFiled: August 24, 2009Publication date: June 30, 2011Applicant: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Yataro Daigo, Akira Togashi
-
Publication number: 20100273855Abstract: The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder cancer, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testicular seminoma.Type: ApplicationFiled: June 26, 2008Publication date: October 28, 2010Applicant: ONCOTHERAPY SCIENCE, INC.Inventors: Akira Togashi, Ryutaro Tobita, Yuka Ishizaki, Akiko Konuma
-
Patent number: 4245697Abstract: A tubular body on whose external surface are formed a series of periodically wavy recesses of specific depth and angle, said recesses becoming the corresponding series of similarly wavy projections and thereby improving the mixed state or heat conduction efficiency of a fluid flowing therein.Type: GrantFiled: November 14, 1979Date of Patent: January 20, 1981Inventor: Akira Togashi
-
Patent number: 4228852Abstract: A tubular body on whose external surface are formed a series of periodically wavy recesses of specific depth and angle, said recesses becoming the corresponding series of similarly wavy projections and thereby improving the mixed state or heat conduction efficiency of a fluid flowing therein.Type: GrantFiled: February 28, 1979Date of Patent: October 21, 1980Inventor: Akira Togashi
-
Patent number: 4206806Abstract: In a heat exchanger, ends of adjacent heat-conducting pipes are flattened to form joining faces and these faces are butt-welded together to form a parallel pipe heat exchanger without end plates.Type: GrantFiled: January 9, 1979Date of Patent: June 10, 1980Inventor: Akira Togashi
-
Patent number: 4175308Abstract: In a heat exchanger, ends of adjacent heat-conducting pipes are flattened to form joining faces and these faces are butt-welded together to form a parallel pipe heat exchanger without end plates.Type: GrantFiled: March 15, 1976Date of Patent: November 27, 1979Inventor: Akira Togashi